Myrexis Inc., a Salt Lake City-based biotechnology research company that idled much of its operations last year, said it is pursing a new long-term strategy.
Part of it will be to explore acquisition opportunities to bring new commercial operations to the company.
To help accomplish that goal, the company said Richard Brewer has been appointed president and CEO, and that David Gryska will be chief operating officer, with both also named to Myrexis’ board of directors.
"The board has been evaluating alternatives to increase shareholder value following our decision in February to suspend development activities on the company’s pre-clinical and clinical programs," Myrexis Chairman Gerald Bell said a statement announcing the executive appointments.
Brewer and Gryska collectively have an extensive track record of commercializing, acquiring and marketing pharmaceutical products, he added. Salt Lake Tribune
